Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhaskar Dasgupta

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|March 10, 2022
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialMaria C Cid, Sebastian H Unizony, Daniel Blockmans, et al.
Frontiers in Immunology|August 29, 2022
Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumaticaRosanne D Reitsema, William F Jiemy, Lieske Wekema, et al.
The New England Journal of Medicine|October 4, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid TaperRobert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al.
Arthritis Research & Therapy|October 15, 2023
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisWolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, et al.
Health Technology Assessment (Winchester, England)|December 8, 2016
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness studyRaashid Luqmani, Ellen Lee, Surjeet Singh, et al.
Rheumatology (Oxford, England)|April 27, 2016
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabNathan Vastesaeger, Abraham Garcia Kutzbach, Howard Amital, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2018
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practiceChristian Dejaco, Sofia Ramiro, Christina Duftner, et al.
Annals of the Rheumatic Diseases|February 6, 2025
GM-CSF drives IL-6 production by macrophages in polymyalgia rheumaticaWilliam F Jiemy, Anqi Zhang, Wayel H Abdulahad, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|March 10, 2022
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialMaria C Cid, Sebastian H Unizony, Daniel Blockmans, et al.
Frontiers in Immunology|August 29, 2022
Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumaticaRosanne D Reitsema, William F Jiemy, Lieske Wekema, et al.
The New England Journal of Medicine|October 4, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid TaperRobert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al.
Arthritis Research & Therapy|October 15, 2023
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisWolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, et al.
Health Technology Assessment (Winchester, England)|December 8, 2016
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness studyRaashid Luqmani, Ellen Lee, Surjeet Singh, et al.
Rheumatology (Oxford, England)|April 27, 2016
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabNathan Vastesaeger, Abraham Garcia Kutzbach, Howard Amital, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2018
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practiceChristian Dejaco, Sofia Ramiro, Christina Duftner, et al.
Annals of the Rheumatic Diseases|February 6, 2025
GM-CSF drives IL-6 production by macrophages in polymyalgia rheumaticaWilliam F Jiemy, Anqi Zhang, Wayel H Abdulahad, et al.
Pageof 21